Business Wire

Panda Biotech Plans the Largest Industrial Hemp Processing Facility for Fiber and Cellulose in the United States

Share

Dallas-based Panda Biotech today announced it is developing its first industrial hemp processing facility to produce high-quality, textile-grade fiber and premium cellulose. The “Panda High Plains Hemp Gin,” to be located in Lubbock County, Texas, is expected to be the largest hemp decortication center in the United States and one of the largest in the world.

Panda Biotech plans on deploying the most technologically advanced, highest capacity and first-of-its-kind industrial hemp decorticating equipment ever used to separate the fiber and cellulose from the stalk. The Panda Biotech Hemp GinsTM will be based on smaller versions of proven decortication technology that have been used throughout Asia and Europe for decades.

To ensure the highest quality fiber, the company will only process hemp stalks that are harvested prior to the maturation of the seed and flower, which are the parts of the plant used in CBD products.

Panda Biotech has also secured the rights to purchase a 255,000 square foot processing facility in Shallowater, Texas in the heart of cotton country. More than 130,000 tons of Texas-grown industrial hemp is expected to be processed annually into textile fiber and cellulose.

In the lead up to today’s announcement, Panda Biotech has engaged key stakeholders in the Texas High Plains region including the local farming community, academic institutions and elected officials. Panda Biotech is also establishing business relationships with large potential off-takers for the fiber and cellulose to be produced at its Texas facility. In addition, the company is assembling a “first in class” advisory board composed of some of the top industrial hemp, textile and cellulose experts in the nation as well as agronomists experienced in the seeding, cultivation and harvesting of industrial hemp.

“After more than a year of due diligence — which has included an analysis of the hemp fiber and cellulose industries in the People’s Republic of China, various European countries and Canada — we have concluded that the processing of hemp stalk for industrial uses will be the next multi-billion-dollar business in the United States,” said Scott Evans, executive vice president of Panda Biotech. “Hemp fiber and cellulose will help manufacturers meet the needs of today’s eco-conscious consumers who increasingly require environmentally friendly products and services. As a result, hemp will be a game changer for both agriculture and industry for generations to come.”

Formation and growth of the industrial hemp industry

The U.S. hemp industry was made possible due to the passage of the federal Hemp Farming Act of 2018. Panda Biotech was subsequently formed after the provisions of the Act were incorporated in the 2018 U.S. Farm Bill that was signed into law by President Trump on Dec. 20, 2018. Both chambers of the Texas state legislature unanimously passed House Bill 1325, that was signed into law on June 10, 2019, by Texas Governor Greg Abbott. The law authorizes the production and manufacture of industrial hemp crops in the State of Texas pending final approval of Texas’ hemp regulations by the USDA which is expected in the coming weeks. The law ensures Texas farmers are able to participate in a rapidly growing industry with a new viable crop option that should also be a boon to rural economies.

The global industrial hemp market is projected to grow from $4.6 billion in 2019 to $32 billion by 2022.

Benefits of industrial hemp fiber and cellulose

Industrial hemp used for manufacturing applications is highly valued for its natural durability, rapid growth and environmental sustainability. The processed fiber and cellulose from industrial hemp can be used in the production of a multitude of products including textiles, a wide array of building materials, paper products, automobile composites, nanomaterials, bio-plastics and finishing products such as caulking, sealants, varnishes and paints. In addition, research indicates that hemp-based supercapacitors offer a less expensive alternative to materials currently used in rechargeable batteries for applications such as smartphones and electric cars. As a result, industrial hemp is poised to transform numerous multi-billion-dollar industries.

About Panda Biotech

Based in Dallas, Texas, Panda Biotech, LLC is a first-mover in the emerging U.S. industrial hemp fiber and cellulose industry. The company is currently developing industrial hemp processing facilities and large-scale Hemp GinsTM. Panda Biotech’s first processing facility is planned for the High Plains region of Texas.

Panda Biotech’s executive leadership has extensive experience developing, financing, constructing and operating large-scale industrial facilities including natural gas, solar, hydroelectric and biomass energy projects. They have developed 22 projects since 1982 representing approximately $14 billion in invested capital. Additional information on Panda Biotech can be found at www.pandabiotech.com. Follow us on Instagram, Twitter and LinkedIn.

Contact information

Media
Open Doors Public Relations
Bill Pentak, Principal
+ 1 (214) 396-6065 X1006
bpentak@OpenDoorsPR.com

For information on investing or business opportunities
Dixie Carter
+1 (214) 396-6065
dixie.carter@pandabiotech.com

Grower inquiries
https://www.pandabiotech.com/contact-grower-inquiries

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Iguazio Raises $24M to Accelerate Growth and Global Penetration of its Data Science Platform27.1.2020 15:00:00 EETPress release

Iguazio, the data science platform for real time machine learning applications, today announced that it has raised $24M of funding. The round was led by INCapital Ventures, with participation from existing and new investors, including Pitango, Verizon Ventures, Magma Venture Partners, Samsung SDS, Kensington Capital Partners, Plaza Ventures and Silverton Capital Ventures. The funds will be used by Iguazio to accelerate its growth and expand the reach of its data science platform to new global markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200127005301/en/ Iguazio co-founders Yaron Segev (left), Yaron Haviv, and Asaf Somekh. Photo: Yanai Yechiel The demand for AI applications is on the rise. According to Gartner, AI augmentation alone will create $2.9 trillion of business value in 2021. However, there are still many challenges in deploying AI solutions in an effective and scalable way. An estimated 87% of data scienc

Iguazio Deployed by Payoneer to Prevent Fraud with Real-time Machine Learning27.1.2020 15:00:00 EETPress release

Iguazio, the data science platform for real time machine learning applications, today announced that Payoneer, the digital payment platform empowering businesses around the world to grow globally, has selected Iguazio’s platform to provide its 4 million customers with a safer payment experience. By deploying Iguazio, Payoneer moved from a reactive fraud detection method to proactive prevention with real-time machine learning and predictive analytics. Payoneer overcomes the challenge of detecting fraud within complex networks with sophisticated algorithms tracking multiple parameters, including account creation times and name changes. However, prior to using Iguazio, fraud was detected retroactively, enabling customers to only block users after damage had already been done. Payoneer is now able to take the same sophisticated machine learning models built offline and serve them in real-time against fresh data. This ensures immediate prevention of fraud and money laundering with predictiv

Oasis Smart SIM Achieves Certification of HELIOS eUICC in Accordance With GSMA M2M Specifications27.1.2020 14:48:00 EETPress release

Oasis’ newly certified HELIOS eUICC Operating System can be used in any type of mobile device, whilst guaranteeing total security and interoperability with the rest of the eSIM ecosystem. This certification was done by an independent accredited laboratory following the GSMA SGP.16 v1.0 validation requirements and processes. Rigorous testing of HELIOS eUICC by a third-party lab verified the compliance with GSMA specifications and standard interoperability. The goal is to ensure that mobile network operators are able to use HELIOS eUICC in complete security and in a reliable manner. To address the market needs, HELIOS eUICC is available both as a software-only Operating System or preloaded into Secure Elements from leading semiconductor companies. Its complete interoperability ensures that HELIOS eUICC can be remotely managed by any Subscription Manager compliant with the GSMA specifications. Patrick Cao, Chief Operating Officer, said “We are proud to obtain this certification. This conf

A Better Alternative to Banking - ClubSwan.com27.1.2020 12:00:00 EETPress release

ClubSwan.com, the leader in membership driven financial solutions, further expands its innovative alternative banking capabilities to key global markets. As traditional financial institutions continually struggle to provide innovative and meaningful ways to bring value to individual and corporate customers and as digital assets/crypto currencies are experiencing global growth, ClubSwan.com continues to evolve to meet the efficiencies and demands that these new assets and our customers require and to which traditional banks have no answer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200127005046/en/ Instead, closed bank accounts, rejected transactions, crippling delays with customers receiving their funds (if at all) are all the norm with traditional banks. To add to this dilemma, the availability of trustworthy solutions where customers have peace of mind for both crypto assets and traditional currencies have been non-exi

GSMA Recognizes Turkcell and P.I. Works for the Value of AI Based Network Automation27.1.2020 10:00:00 EETPress release

Turkcell and P.I. Works have been recognized by GSMA Future Networks Programme for achieving exceptional efficiency gains in network operations and ensuring superior customer experience. P.I. Works and Turkcell have successfully shown that the AI based, service aware network automation delivered stronger improvements as compared to conventional automation solutions. The details of the deployed solutions and their benefits are provided in a joint white paper authored by GSMA, Turkcell and P.I. Works under GSMA’s Future Networks Programme. To read the white paper please visit: https://www.gsma.com/futurenetworks/wiki/case-study-ai-use-cases-in-service-assurance/ GSMA Future Networks Programme intends to help operators share best practices and discover new opportunities that will enable them to reduce operational and capital expenditures. Given the success of the project, GSMA invited Turkcell and P.I. Works to join the program and provide insights for the AI-based, Service Aware Automate

Phase 2 DESTINY-Gastric01 Trial of DS-8201 Versus Chemotherapy Met Primary Endpoint27.1.2020 10:00:00 EETPress release

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca today announced positive topline results from the pivotal phase 2 DESTINY-Gastric01 trial of DS-8201, a HER2 directed antibody drug conjugate (ADC), in patients with HER2 positive unresectable or metastatic gastric or gastroesophageal junction cancer that had progressed following two or more treatment regimens including trastuzumab and chemotherapy. The trial met its primary endpoint, achieving a statistically significant and clinically meaningful improvement in objective response rate (ORR), as assessed by an independent review committee, in patients treated with DS-8201 versus investigator’s choice of chemotherapy (irinotecan or paclitaxel monotherapy). DS-8201 also showed a statistically significant and clinically meaningful improvement in overall survival (OS), a key secondary endpoint. The safety profile observed for DS-8201 in DESTINY-Gastric01 was consistent with previous clinical trials. These results c

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom